CNS Depressants/Antianxiety Agents
Dr.Peter Winsauer
- CNS depressants
- Barbiturates
- Classification according to their rate of onset and duration of action
a)Ultrashort-acting barbiturates
1)Thiopental – t1/2 = 12 hr. (duration of induction 5-8 min)
2)Thiamylal
3)Methylhexital – t1/2 = 4 hr.
b)Short- to intermediate-acting barbiturates
1)Secobarbital (Seconal) – t1/2 = 15-40 hr.
2)Pentobarbital (Nembutal) – t1/2 = 15-50 hr.
c)Long-acting barbiturates
1)Phenobarbital (Luminal) – t1/2 = 80-120 hr.
- Pharmacokinetics
a)Rate of distribution depends on their lipid solubility.
b)Metabolism can be altered by induction of hepatic enzymes.
- Mechanism of action
a)Bind to a specific site on GABAA receptors
b)Facilitate the actions of GABA
c)Can activate the GABAA receptor directly at large concentrations
- Clinical uses
a)Induction of anesthesia
b)Treatment of some forms of epilepsy
- Adverse effects
a)CNS depression (i.e., sedation)
b)Respiratory depression
c)Tolerance
d)Dependence
e)Abuse
- Drug interactions
a)Additive effects with other CNS depressants
b)Induction of hepatic enzymes can accelerate metabolism of other drugs.
- Benzodiazepines
- Classification according to their rate of onset and duration of action
a)Short-acting
1)Midazolam (Versad) – t1/2 = 2 hr.
2)Triazolam (Halcion) – t1/2 = 3 hr.
b)Intermediate-acting
1)Lorazepam (Ativan), t1/2 = 14 hr.
2)Oxazepam (Serax), t1/2 = 8 hr.
3)Temazepam (Restoril), t1/2 = 11 hr.
4)Alprazolam (Xanax), t1/2/= 12 hr.
5)Chlordiazepoxide, t1/2 = 10 hr.
c)Long-acting
1)Flurazepam, t1/2 = 74 hr.
2)Diazepam, t1/2 = 43 hr.
3)Clonazepam, t1/2 = 23 hr.
- Pharmacokinetics
a)Metabolism can result in the formation of active metabolites.
- Mechanism of action
a)Bind to a specific site on the GABAA receptor
b)Facilitate the actions of GABA
c)Do NOT activate the GABAA receptor directly
- Clinical uses
a)Anxiolytic effects
b)Sedative effects
c)Muscle relaxant effects
d)Anticonvulsant effects
e)Induction of anesthesia
- Adverse effects
a)CNS depression (i.e., sedation)
b)Anterograde amnesia
c)Respiratory depression
d)Tolerance
e)Dependence
f)Abuse potential
- Drug interactions
a)Additive effects with other CNS depressants
- Anxiety
- Types of anxiety disorders
- Generalized anxiety disorder—persistent state of heightened anxiety with increased levels of motor tension and autonomic hyperactivity
- Panic disorder—recurrent, discrete periods of sudden and intense fear or discomfort accompanied by autonomic arousal
- Treatment of anxiety disorders
- Benzodiazepines
a)Immediate anxiolytic effects
b)Alprazolam—only benzodiazepine marketed for panic disorder
- Buspirone
a)Serotonin agonist
b)Long latency to obtain anxiolytic effects
c)Not effective in treating panic disorder
d)Adverse effects include headache, dizziness and nausea
- Antidepressants—first choice for treatment of panic disorder
a)SSRIs
b)Tricyclic antidepressants
c)MAO inhibitors
- Beta blockers—used to prevent performance anxiety
- Insomnia
- Causes of insomnia
- Stress or emotional upset
- Aging
- Medical and psychiatric illness
- Drugs/Alcohol
- Sleep cycle disruption (jet lag)
- Treatment of insomnia
- Benzodiazepines
a)Triazolam – t1/2 = 3 hr.
b)Flurazepam – t1/2 = 74 hr.
c)Temazepam (Restoril) – t1/2 = 11 hr.
2.Non-benzodiazepines that bind to the BZ1 site
d)Zolpidem (Ambien) – t1/2 = 2 hr.
e)Zaleplon (Sonata) – t1/2 = 1 hr.
f)Eszopiclone (Lunesta)
3.Chloral Hydrate – SHOULD NOT BE USED!
- Antidepressants
- Antihistamines – e.g., hydroxyzine